“The Global Glioblastoma Multiforme Treatment Market was valued at US$ 698.3 Mn in 2018 and is expected to grow at a significant CAGR over six years forecast period 2019-2025 owing to increasing prevalence of cancer and increasing awareness about the advanced treatments available in the market”
Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The global glioblastoma multiforme treatment market was valued at US$ 698.3 Mn in 2018 and growing at a CAGR of XX% over the forecast period owing to increasing awareness regarding the brain tumor coupled with number of organizations spreading awareness regarding the availability of new therapies to treat glioblastoma multiforme which is a stage IV brain cancer. Most of the patients of GBM are unconscious and intravenous treatment creates huge demand in the future years. Number of generic market players are entering into the market with generic intravenous treatment for GBM to enhance and increase the accessibility to the patients. Advancements in technology for the early diagnosis of disease and accessibility of novel medications for the treatment of GBM drives the growth of the market. Moreover, increasing support from the government for such costly medicines to increase accessibility to the poor ones fuels the growth of the market. However, high expenditure involved in research employing genomics based research is a key restraint for market.
Global glioblastoma multiforme treatment market segmented on the basis of drug type, end user, and region.
Request Sample Report:
Temozolomide segment accounted for higher revenue share
Based on drug type, global glioblastoma multiforme treatment market segmented into Temozolomide, Bevacozumab, carmustine, Radiosensitizers, and Others. Temozolomide accounted for the largest market share in 2018 with respect to revenue owing to the beneifts offered by the drug which include delayed progression without impacting on quality of life and comparatively less adverse effects of the molecule. Temozolomide is the only molecule that has 99.9% of bioavailability and has very less adverse reactions coupled with the drug is also available with number of market players with generic brands and is available in intravenous form. Moreover, methylated or alkylated DNA in the structural anomalies of the drug produces a better therapeutic efficacy thus leading to higher preference of the drug over the other segments. On the contrary, pipeline drugs under phase III trials such as Rindopepimut (CDX-110) and DCVax are expected to be the fastest growing segment over the forecast period as a consequence of observation of adverse events in adult patient base with the use of the available drug options.
North America holds leading position in Global Glioblastoma Multiforme Treatment Market
PBI’s global glioblastoma multiforme treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to the increasing adoption of patients to the novel treatments available in the market and availability of flexible reimbursement policies in the region drives the growth of the market. Increasing incidence of cancer and rising geriatric population fuels the growth of the market in the region. Availability of generic products for glioblastoma multiforme in Asia Pacific region is anticipated to enhance the growth of the market and increasing prevalence and early diagnosis of disease condition in the region fuels the growth of the market over the forecast period.
Recent Developments in the Global Glioblastoma Multiforme Treatment Market
- In 2015, CANbridge Life Sciences acquired license for to develop, manufacture and commercialize Apogenix’s APG101 onco-immunotherapy in glioblastoma for China..
Key player’s profiles in the report are Merck & Co Inc. (U.S.), Teva Pharmaceutical Industries, Ltd. (Israel), Arbor Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Celldex Therapeutics, Inc. (U.S.), Bristol-Myers Squibb Co. (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), Apogenix (Germany), Pfizer, Inc. (U.S.), and Vascular Biogenics (Israel).
By Drug Type
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Middle East and Africa (MEA)
By End User
- Rest of Europe
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- South Africa
- Rest of MEA
For More Information:
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
Contact Us: Shreya Paul
Senior Business Development Executive
Call @ +1-866-598-1553
Precision Business Insights Toll Free (US): +1-866-598-1553